Matthieu Ducharme joins AXA IM Prime as Head of Private Equity Secondaries
- 30 November 2023
AXA Investment Managers (AXA IM) has today announced the appointment of Matthieu Ducharme as Head of Private Equity Secondaries at AXA IM Prime, the Private Markets Enabler and Hedge Funds platform of AXA IM. Based in London, he starts with immediate effect and reports to Peter Ischebeck, Head of Private Equity at AXA IM Prime.
In this newly created role, Matthieu Ducharme is responsible for all aspects of AXA IM Prime’s private equity secondaries strategy, overseeing the sourcing and execution of transactions, as well as the development of secondary products.
Commenting on the appointment, Pascal Christory, Chief Executive Officer of AXA IM Prime said: “We are delighted to welcome Matthieu as Head of AXA IM Prime’s private equity secondaries activities. Our secondary offering is an important part of AXA IM Prime’s holistic approach to private markets and builds on our well-established private equity program. Matthieu brings a wealth of experience in scaling private equity secondaries programs globally, and his deep sector expertise will be invaluable to investors and General Partners (GPs) looking to take advantage of the strong growth in the secondary market.”
Matthieu Ducharme’s appointment builds on AXA IM Prime’s ongoing expansion in private markets with a number of new products launched in recent months and a fast-growing team since its establishment last year. AXA IM Prime currently holds €34 billion of assets under management1 and embraces a diverse range of private market strategies across private equity, infrastructure equity, private debt and hedge funds.
- QXNzZXRzIHVuZGVyIG1hbmFnZW1lbnQgb3IgYWR2aXNvcnksIGFzIG9mIHRoZSBlbmQgb2YgU2VwdGVtYmVyIDIwMjMu
Biography
Matthieu Ducharme
Prior to joining AXA IM Prime, Matthieu Ducharme was a Managing Director at Northleaf Capital, a global private markets investment firm with $23 billion in capital commitments raised. During his 10-year tenure at Northleaf, Matthieu was instrumental in the launch and expansion of the firm’s private equity secondaries program. In addition to developing a strong track record across all types of secondary transactions globally, Matthieu also expanded Northleaf’s primary and co-investment activities in Europe. Altogether, he contributed to the deployment of over $2 billion across 80 investments. Matthieu also chaired the firm’s Private Equity ESG Committee, leading on a number of initiatives to meet the best industry standards.
Previously, Matthieu co-founded PEFOX, a private equity secondaries intermediary, originally focused on complex secondary transactions and private equity derivatives.
Matthieu started his career with Pantheon Ventures’ secondaries team in London where he was responsible for the sourcing, evaluation and negotiation of portfolio, fund and direct secondary transactions across Europe, the US and Asia.
Matthieu received an M.Sc. in Financial Engineering from the Sorbonne University and a B.Sc. in Management Science & Finance from Dauphine University in Paris.
About AXA IM Prime
Launched in 2022, AXA IM Prime is the Private Markets Enabler and Hedge Funds platform of AXA IM with c. €34 billion of assets under management. It offers global and diversified private market solutions through primaries, secondaries and co-investments across private equity, infrastructure equity, private debt and hedge funds.
As both a principal investor and a General Partner, AXA IM Prime holds a deep understanding of client needs and offers a differentiated, global perspective of the investment world. It aims to create sustainable value for its clients, integrating ESG practices and encouraging ESG best practices within the industry.
Visit our website: https://www.axa-im.com/prime
This press release does not constitute on the part of AXA Investment Managers a solicitation or investment, legal or tax advice. This material does not contain sufficient information to support an investment decision.
Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.
Before making an investment, investors should read the relevant Prospectus and the Key Investor Information Document / scheme documents, which provide full product details including investment charges and risks. The information contained herein is not a substitute for those documents or for professional external advice.
The products or strategies discussed in this document may not be registered nor available in your jurisdiction. Please check the countries of registration with the asset manager, or on the web site https://www.axa-im.com/en/registration-map, where a fund registration map is available. Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in the European Union country by notification to its authority of supervision in accordance with European passport rules. In particular units of the funds may not be offered, sold or delivered to U.S. Persons within the meaning of Regulation S of the U.S. Securities Act of 1933. The tax treatment relating to the holding, acquisition or disposal of shares or units in the fund depends on each investor’s tax status or treatment and may be subject to change. Any potential investor is strongly encouraged to seek advice from its own tax advisors.
Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units.
Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office: 22 Bishopsgate London EC2N 4BQ
In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.